Prescient Therapeutics Ltd. has appointed a highly respected US-based specialist in myeloid malignancies Dr. Thomas Prebet MD, PhD of Yale Cancer Center to the PTX Scientific Advisory Board (SAB). Dr. Prebet is the Assistant Director of Myeloid Malignancy Research at Yale, where he is working to
expand the clinical and translational research program in myeloid malignancies. Dr. Prebet was previously with the Institut Paoli-Calmettes in Marseille France where he was an Associate Professor of Clinical Hematology and a member of the molecular pharmacology group, as well as the early phase trial group and coordinator of the leukemia ward.